STAAR Surgical Company (STAA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on January 6, 2026. STAAR Surgical Company (the "Company") reports the termination of a previously announced merger agreement and the results of a special meeting of stockholders held to vote on the transaction.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The document focuses exclusively on corporate governance and transactional events.
Material Changes and Events
- Termination of Merger Agreement: The Agreement and Plan of Merger dated August 4, 2025, between STAAR Surgical, Alcon Research, LLC ("Alcon"), and Rascasse Merger Sub, Inc. was terminated effective January 6, 2026.
- Termination Fees: No termination fees are payable by the Company, Alcon, or Merger Sub. Each party will bear its own costs and expenses related to the agreement.
- Stockholder Vote Results: A special meeting was held on January 6, 2026. Approximately 87.9% of outstanding shares were present or represented by proxy. Both proposals were rejected by stockholders:
| Proposal | Votes For | Votes Against | Abstentions | Result |
|---|---|---|---|---|
| 1. Adoption of Merger Agreement | 14,904,915 | 27,339,877 | 1,123,136 | Not Approved |
| 2. Advisory Compensation Approval | 14,224,065 | 27,905,792 | 1,238,071 | Not Approved |
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the immediate context of the failed transaction. The primary outcome is the cessation of the planned merger with Alcon.
Key Facts for Investor Verification
- Verify the Company's immediate capital position and liquidity following the termination of the merger.
- Confirm whether the Company has announced any alternative strategic plans or operational pivots post-merger failure.
- Review the specific reasons for the stockholder rejection of the merger proposal (e.g., valuation concerns, deal structure) in subsequent press releases or investor communications.
- Monitor for any potential legal disputes or regulatory filings related to the termination of the agreement with Alcon.